March 29, 2017

Afimmune’s DS102 receives FDA fast track designation as an investigational treatment for patients suffering from NASH with liver fibrosis

Dublin, Ireland, 29th March 2017: Afimmune, a privately held biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted fast track […]